RT Journal Article
SR Electronic
T1 Manifestations Associated with Post Acute Sequelae of SARS-CoV2 Infection (PASC) Predict Diagnosis of New-Onset Psychiatric Disease: Findings from the NIH N3C and RECOVER Studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.08.22277388
DO 10.1101/2022.07.08.22277388
A1 Ben Coleman
A1 Elena Casiraghi
A1 Tiffany J Callahan
A1 Hannah Blau
A1 Lauren Chan
A1 Bryan Laraway
A1 Kevin B. Clark
A1 Yochai Re’em
A1 Ken R. Gersing
A1 Ken Wilkins
A1 Nomi Harris
A1 Giorgio Valentini
A1 Melissa A Haendel
A1 Justin Reese
A1 Peter N Robinson
A1 the N3C consortium
A1 the RECOVER Consortium
YR 2022
UL http://medrxiv.org/content/early/2022/07/09/2022.07.08.22277388.abstract
AB Acute COVID-19 infection can be followed by persistent or newly diagnosed manifestations in many different organ systems, referred to as Post Acute Sequelae of SARS-CoV2 Infection (PASC). Numerous studies have shown an increased risk of being diagnosed with new-onset psychiatric disease in the first 21-120 days following a diagnosis of acute COVID-19. However, it was unclear whether non-psychiatric PASC-associated manifestations (PASC-AMs) are associated with an increased risk of receiving a diagnosis of new-onset psychiatric disease following COVID-19.Here, we perform a retrospective electronic health record (EHR) cohort study to evaluate whether non-psychiatric PASC-AMs can predict whether patients will receive a diagnosis of new-onset psychiatric disease. Data were obtained from the National COVID Cohort Collaborative (N3C), which has EHR data from 65 clinical organizations which are harmonized using the Observational Medical Outcomes Partnership (OMOP) data model. Non-psychiatric PASC-AMs were recorded 21-120 days following SARS-CoV-2 diagnosis and before diagnosis of new-onset psychiatric disease. OMOP codes were mapped to 178 Human Phenotype Ontology (HPO) terms that represent PASC-AMs. Logistic regression was applied to predict newly diagnosed psychiatric disease occurrence based on age, sex, race, pre-existing comorbidities, and PASC-AMs in eleven categories.The cohort of 1,135,973 individuals with acute COVID-19 had a mean age of 40.5 years and included 56.0% females. We found a significant association for seven of the HPO categories with newly diagnosed psychiatric disease, with odds ratios highest for neurological (2.30, 2.24-2.36) and cardiovascular (1.77, 1.69-1.85) PASC-AMs. Secondary analysis revealed that the proportions of 95 of 154 individual phenotypic features differed significantly among patients diagnosed with different psychiatric diseases (anxiety, mood disorders, dementia, and psychosis). Neurological, pulmonary, gastrointestinal, endocrine, cardiovascular, constitutional, and ENT PASC-AMs are each associated with an increased risk of newly diagnosed psychiatric disease. This suggests that the total burden of PASC-AMs influences the risk of receiving a diagnosis of a new-onset psychiatric disease. This finding may be used to inform psychiatric screening following acute COVID-19 by identifying high-risk patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NCATS U24 TR002306.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was exempted by the Institutional Review Board (IRB) at the Jackson Laboratory under 45 CFR 46.101(b) (Common Rule). The National Covid Cohort Collaborative (N3C) data transfer to the National Center for Advancing Translational Sciences (NCATS) is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with the National Institute of Health (NIH). The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this paper can be accessed upon application to the NCATS N3C Data Enclave at https://covid.cd2h.org/enclave. https://covid.cd2h.org/enclave